Nasdaq:HUMA

DURHAM, N.C., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human…

DURHAM, N.C., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human…

DURHAM, N.C., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human…

-- Preclinical model data expected to support development of small diameter HAV to treat patients with coronary artery disease-- -- Small-diameter HAV observed to maintain patency and…

-- HAV remained patent and host-cell remodeling was observed in non-human primate model -- -- Preclinical study represents milestone in the development of small-diameter HAVs for use in…

DURHAM, N.C., Dec. 31, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human…

– Performance of HAVs produced in the LUNA200™ commercial-scale system demonstrated efficacy that is similar to prior HAV performance in dialysis access trials – – 83% secondary patency…

Patent estate also expanded by the issuance of 23 additional patents in international marketsHumacyte now owns or licenses 119 patents covering its proprietary platform DURHAM, N.C.,…

DURHAM, N.C., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human…